Annotated Medicine and Device Lists
| List | Section | Observation |
|---|---|---|
| PAHO Strategic Fund Medicine List | 2.6.1. Antiretrovirals |
Others observations: Procurement of this medicine through the Strategic Fund should be limited for use as third-line therapy in treatment-experienced HIV adults who failed second-line antiretroviral therapy. It is recommended patients receiving HIV/AIDS regimens including this medicine be monitored for potential adverse events or related toxicities through national pharmacovigilance programs and data from the WHO Programme for International Drug Monitoring (UPPSALA). |
| List | Section | Observation |
|---|---|---|
| PAHO Strategic Fund Medicine List | 2.6.1. Antiretrovirals |
Others observations: Procurement of this medicine through the Strategic Fund should be limited for use as third-line therapy in treatment-experienced HIV adults who failed second-line antiretroviral therapy. It is recommended patients receiving HIV/AIDS regimens including this medicine be monitored for potential adverse events or related toxicities through national pharmacovigilance programs and data from the WHO Programme for International Drug Monitoring (UPPSALA). |